Your browser doesn't support javascript.
loading
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
Nijhof, Inger S; Franssen, Laurens E; Levin, Mark-David; Bos, Gerard M J; Broijl, Annemiek; Klein, Saskia K; Koene, Harry R; Bloem, Andries C; Beeker, Aart; Faber, Laura M; van der Spek, Ellen; Ypma, Paula F; Raymakers, Reinier; van Spronsen, Dick-Johan; Westerweel, Peter E; Oostvogels, Rimke; van Velzen, Jeroen; van Kessel, Berris; Mutis, Tuna; Sonneveld, Pieter; Zweegman, Sonja; Lokhorst, Henk M; van de Donk, Niels W C J.
  • Nijhof IS; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Franssen LE; Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands.
  • Levin MD; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Bos GMJ; Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands.
  • Broijl A; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • Klein SK; Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Koene HR; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Bloem AC; Department of Internal Medicine, Meander Medical Center, Amersfoort, The Netherlands.
  • Beeker A; Department of Hematology, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Faber LM; Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van der Spek E; Department of Internal Medicine, Spaarne Hospital, Hoofddorp, The Netherlands.
  • Ypma PF; Department of Internal Medicine, Rode Kruis Hospital, Beverwijk, The Netherlands.
  • Raymakers R; Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
  • van Spronsen DJ; Department of Internal Medicine, HagaZiekenhuis, Den Haag, The Netherlands; and.
  • Westerweel PE; Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands.
  • Oostvogels R; Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • van Velzen J; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
  • van Kessel B; Department of Hematology, University Medical Center Utrecht Cancer Center, Utrecht, The Netherlands.
  • Mutis T; Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Sonneveld P; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Zweegman S; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
  • Lokhorst HM; Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
  • van de Donk NWCJ; Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
Blood ; 128(19): 2297-2306, 2016 11 10.
Article en En | MEDLINE | ID: mdl-27647864
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Talidomida / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Ciclofosfamida / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Talidomida / Prednisona / Protocolos de Quimioterapia Combinada Antineoplásica / Resistencia a Antineoplásicos / Ciclofosfamida / Mieloma Múltiple Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article